Związek między stężeniami lipokaliny-2 i testosteronu wolnego w zespole policystycznych jajników

Abstract

Introduction: Lipocalin-2 is an adipokine that is mainly produced from adipocytes and macrophages. Data related to PCOS and other obesity-associated disorders have shown divergent results. Here, we studied lipocalin-2 concentrations in women with PCOS and in healthy women, and investigated the potential contributors underlying lipocalin association with PCOS. Material and methods: Forty-four women with PCOS and 47 age-and BMI-matched healthy women were enrolled. Fasting serum glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hs-CRP), and free testosterone levels were measured. The body fat percentage was measured by bioelectrical impedance. Results: Lipocalin-2 concentrations were significantly higher in the PCOS group than in the control group (55.74 ± 17.54 ng/mL vs. 36.46 ± 19.62 ng/mL, p = 0.011). There was a correlation between lipocalin-2 levels and free testosterone. In a multiple regression model, the body fat percentage, HOMA-IR, and hs-CRP were not associated with lipocalin-2. However, only free testosterone was associated with lipocalin-2. A "lipocalin-2 = 11.214 + (1.943 × free-testosterone)" equation was obtained. Conclusions: Serum lipocalin-2 levels were higher in women with PCOS, and only free testosterone was associated with lipocalin-2. Lipocalin-2 levels and their influencing factors have discrepant results in both PCOS and other obesity-or insulin resistance-related metabolic disorders. Thus, the potential role of lipocalin-2 in PCOS should be clarified. (Endokrynol Pol 2017; 68 (1): 7-12)

Review of Novel Potential Insulin Resistance Biomarkers in PCOS Patients—The Debate Is Still Open

“…Cakal et al have performed a cross-sectional study investigating LCN2 as an insulin resistance marker in the PCOS population and found considerably higher serum lipocain-2 levels in PCOS individuals than in age- and BMI-matched healthy controls [ 185 ]. Similar outcomes have been presented by Yilmaz et al [ 35 ]. In the study by Panidis et al, LCN2 serum levels were slightly elevated, but the results were not statistically significant, despite the greater number of participants.…”

“…However, the study and control groups did not differ in terms of HOMA-IR [ 177 ]. Indeed, HOMA-IR values significantly differed between the PCOS and control groups in the formerly mentioned studies by Cakal et al [ 185 ] and Yilmaz et al [ 35 ].…”

“…It has been confirmed, in animal studies that LCN2 deficiency may protect from the development of insulin resistance through regulation of lipoxygenase and cachexin levels in adipose tissue [ 180 ]. Since the first decade of the 21 st century, LCN2 has gathered a growing interest, due to its potential role as a biomarker for PCOS; nevertheless, the results of studies aiming to confirm this hypothesis remain ambiguous [ 35 , 177 , 181 , 182 , 183 , 184 , 185 , 186 ].…”

“…Surprisingly, there have also been reports of lower LCN2 levels in PCOS patients than in healthy individuals [ 181 , 186 , 187 ], thus emphasizing the need for larger studies. There also exist divergent data when it comes to relation of LCN level to HOMA-IR, as a correlation between them has been determined in some studies [ 177 , 185 ], but not found in others [ 35 , 186 ]. In the latest study, Cheng et al observed the association between LCN-2 serum level and diabetes mellitus progression in PCOS patients [ 187 ].…”